Highly glycosylated human blood-clotting factor VIII fusion protein, and manufacturing method and application of same
A highly glycosylated human blood-clotting factor VIII (FVIII) fusion protein, and a manufacturing method and application of same. The fusion protein comprises, from the N-terminus to the C-terminus, a human (FVIII), a flexible peptide connector, at least one rigid unit of a human chorionic gonadotropin β-subunit carboxyl terminal peptide, and a half-life extending portion (preferentially selected from a human IgG Fc variant). The fusion protein has a similar level of biological activity as a recombinant (FVIII) and an extended in vivo half-life, thereby improving pharmacokinetics and drug efficacy.
1. A fusion protein, wherein the fusion protein has the amino acid sequence of SEQ ID NO: 16.
2. A pharmaceutical composition comprising a pharmaceutically acceptable carrier, excipient and/or diluent, and an effective amount of a fusion protein of claim 1 .
3. A method for preparing a fusion protein, including steps comprising:
(a) introducing a DNA molecule encoding a fusion protein of claim 1 into a CHO cell to produce a CHO-derived cell line;
(b) screening the cell strains of step (a) to obtain a high-yield cell strain expressing more than 1 IU/10 6 (million) cells per 24 h in its growth medium;
(c) culturing the cell strain obtained in step (b) to express the fusion protein; and
(d) harvesting the fermentation broth of step (c) and isolating and purifying the fusion protein.
4. A method for treating hemorrhagic diseases in patients with congenital or acquired FVIII deficiency or for treating spontaneous or surgical bleeding in patients with hemophilia A, comprising administrating an effective amount of a fusion protein of claim 1 to the patient.